Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives

Jonathan M. Lehman; Pierre P. aMassion

doi:10.18632/oncotarget.27107

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives

Jonathan M. Lehman _ and Pierre P. aMassion

PDF | Full Text | How to cite

Oncotarget. 2019; 10:4727-4730. https://doi.org/10.18632/oncotarget.27107

Metrics: PDF 1192 views | Full Text 1769 views | ?

Abstract

Jonathan M. Lehman1^,2^,3 and Pierre P. aMassion1^,2^,3

1 Division of Medical Oncology, Thoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA

2 Thoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA

3 Veterans Affairs, Tennessee Valley Healthcare System, Nashville Campus, Nashville, TN, USA

Correspondence to:

Jonathan M. Lehman,

email:

[email protected]

Keywords: small cell lung cancer; somatostatin receptor 2; antibody-drug conjugate; peptide drug conjugate; perspectives

Received: June 18, 2019 Accepted: June 29, 2019 Published: July 30, 2019

ABSTRACT

Small Cell lung carcinoma (SCLC) is the most lethal and aggressive subtype of lung cancer. Novel targeting approaches and agents are desperately needed. In this perspectives, we briefly explore recent data published in the International Journal of Cancer suggesting Somatostatin Receptor 2 (SSTR2) as a viable target for SCLC, summarize the current clinical trial space, and describe promising new research and clinical directions for Somatostatin Receptor 2 targeting in SCLC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27107

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Perspectives:

Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives

Abstract